Activity
618 followers
-
John Clark liked thisJohn Clark liked thisToday marks my final day with Lytx, Inc., and as I reflect on the past 17 years, I am filled with immense pride. Serving as chairman and CEO has truly been the highlight of my career. When I joined this small, struggling company in 2008, I was motivated by the opportunity to help build something extraordinary. Over nearly two decades, we not only achieved the goal of creating a great company, but we also accomplished the rare feat of founding an entirely new industry—Video Telematics. Along the way, we empowered world-class companies to reach their full potential, we supported our employees to thrive both professionally and personally, and we provided a platform for our investors to prosper. And most importantly, we saved thousands of lives by preventing vehicle collisions that would have otherwise occurred. It’s rare to be part of an endeavor that benefits everyone involved, and I am deeply grateful to have been part of the one-team, one-rope culture that made this all possible. I want to extend my heartfelt thanks to the incredible employees, clients, partners, and investors of Lytx. While we’ve accomplished so much together, I know the company’s journey is only beginning. With over 100 million commercial vehicles still in need of our technology, the future holds immense promise. As I look ahead to the next chapter in my life, I’m uncertain of exactly where it will take me, but I am certain that Lytx will continue to grow, flourish, and help great companies become even greater. I’ll be cheering from the sidelines, filled with pride and deep gratitude.
-
John Clark liked thisExcited to join CastleCreek and lead the company on the next phase of its journey!John Clark liked thisOur team is excited to welcome President and Chief Executive Officer Matthew Gantz, whose visionary leadership will guide Castle Creek Biosciences to further progress and expand our cell-based, #genetherapy pipeline with the ultimate goal of making a difference in the lives of patients and families suffering from serious orphan conditions. Matt comes to us with more than 25 years of experience in the specialty #biopharmaceutical and medical device industries. We look forward to Matt’s expertise and insights as we continue to advance our clinical development programs for dystrophic epidermolysis bullosa and localized scleroderma. For details, see our press release: https://lnkd.in/dCY7u38 Paragon Biosciences
-
John Clark liked thisJohn Clark liked thisGrateful that I made the list of top BHS deals in 2018 #brownharrisstevens #nycrealestate #luxuryrealestate
Experience & Education
Other similar profiles
Explore more posts
-
Anjli Jain
**Boston's Startup Ecosystem Awaits: Founder Summit 2026** As the startup ecosystem continues to thrive, events like the TechCrunch Founder Summit provide invaluable opportunities for founders and investors to connect. ElevenX Capital recognizes that concentrated deal flow facilitates impactful partnerships and consistent innovation in the VC landscape. How do you leverage industry events to enhance your investment strategy? #investing #innovation #venturecapital #entrepreneurship
-
Eric Berry
GLP-1s changed the demand curve for pharmaceuticals. The Most Favored Nation component of TrumpRx will change the supply curve. But counterintuitively, this may lead to the creation a clearinghouse for pharma outcomes, if/when payments start to hinge on results. By tying Medicare reimbursement for certain drugs to the lowest global price, the government is standardizing the reference point for value. That shift starts in Medicare, but it's likely that's where it ends. Private payers, PBMs, and employer plans will use Medicare pricing as a reference point. Drug spend is the fastest-growing component of Medicare Part D, up 7–9% annually. MFN pricing compresses margins for both plans (who manage benefit design) and manufacturers (who rely on U.S. price premiums). This means change will cascade through the industry. Once price ceilings exist, manufacturers can preserve margin by tying revenue to performance. MFN pressure can make this model mainstream - it offers a path to justify higher reimbursement under transparency constraints. But it only works if outcomes can be measured and reconciled automatically. All of requires data integration across claims, EHRs, labs, and pharmacy feeds, creating a true need for an economic verification layer - much like Stripe, but for healthcare.
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content